People · Operator
Named in public records as an officer, director or promoter · active 2015–2019 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Arbor Biotechnologies, Inc. | — | Biotechnology | Series D+ | $230.6M | $5.7B | 2017 |
| Exicure, Inc. | — | Biotechnology | Series C | $85.9M | $901.1M | 2017 |
| Quanterix Corp | — | Other Technology | Series C | $71.8M | $194.1M | 2019 |
| Ultivue, Inc. | — | Biotechnology | Series B | $55.2M | $23.4M | 2015 |
| AuraSense Therapeutics, LLC | — | Biotechnology | Series A | $33.6M | $535.0M | 2015 |
David R. Walt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David R. Walt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Keith Crandell | 3 | 11 |
| Paul Meister | 2 | 12 |
| David Walt | 2 | 6 |
| Helen S. Kim | 2 | 6 |
| David S. Snyder | 2 | 3 |
| Jay R. Venkatesan | 2 | 3 |
| C. Shad Thaxton | 2 | 2 |
| David A. Giljohann | 2 | 2 |
| John Murphy | 1 | 17 |
| John Connolly | 1 | 14 |
| Chen Yu | 1 | 7 |
| John M. Connolly | 1 | 6 |
| Andrea Jackson | 1 | 6 |
| Douglas Cole | 1 | 5 |
| David Okrongly | 1 | 4 |
| Marijn Dekkers | 1 | 4 |
| PAUL M MEISTER | 1 | 4 |
| Mark Angelino | 1 | 4 |
| Chad Mirkin | 1 | 4 |
| Chad A. Mirkin | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.